CA2881096C - Neuroprotective liposome compositions and methods for treatment of stroke - Google Patents

Neuroprotective liposome compositions and methods for treatment of stroke Download PDF

Info

Publication number
CA2881096C
CA2881096C CA2881096A CA2881096A CA2881096C CA 2881096 C CA2881096 C CA 2881096C CA 2881096 A CA2881096 A CA 2881096A CA 2881096 A CA2881096 A CA 2881096A CA 2881096 C CA2881096 C CA 2881096C
Authority
CA
Canada
Prior art keywords
composition
liposomes
stroke
elip
xenon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2881096A
Other languages
English (en)
French (fr)
Other versions
CA2881096A1 (en
Inventor
Shao-ling HUANG
Melvin E. Klegerman
Yong-Jian Geng
Hyunggun KIM
David D. Mcpherson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Priority to CA3132444A priority Critical patent/CA3132444C/en
Publication of CA2881096A1 publication Critical patent/CA2881096A1/en
Application granted granted Critical
Publication of CA2881096C publication Critical patent/CA2881096C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2881096A 2012-08-10 2013-08-09 Neuroprotective liposome compositions and methods for treatment of stroke Active CA2881096C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3132444A CA3132444C (en) 2012-08-10 2013-08-09 Neuroprotective liposome compositions and methods for treatment of stroke

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261682130P 2012-08-10 2012-08-10
US61/682,130 2012-08-10
CN201210356929.9A CN103565745A (zh) 2012-08-10 2012-09-21 用于治疗中风的神经保护性脂质体组合物和方法
CN201210356929.9 2012-09-21
PCT/US2013/054349 WO2014026117A2 (en) 2012-08-10 2013-08-09 Neuroprotective liposome compositions and methods for treatment of stroke

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3132444A Division CA3132444C (en) 2012-08-10 2013-08-09 Neuroprotective liposome compositions and methods for treatment of stroke

Publications (2)

Publication Number Publication Date
CA2881096A1 CA2881096A1 (en) 2014-02-13
CA2881096C true CA2881096C (en) 2021-11-16

Family

ID=50039028

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2881096A Active CA2881096C (en) 2012-08-10 2013-08-09 Neuroprotective liposome compositions and methods for treatment of stroke
CA3132444A Active CA3132444C (en) 2012-08-10 2013-08-09 Neuroprotective liposome compositions and methods for treatment of stroke

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3132444A Active CA3132444C (en) 2012-08-10 2013-08-09 Neuroprotective liposome compositions and methods for treatment of stroke

Country Status (7)

Country Link
US (4) US10369103B2 (https=)
EP (2) EP3932394B1 (https=)
JP (1) JP6297040B2 (https=)
CN (2) CN110464709A (https=)
AU (1) AU2013299453B2 (https=)
CA (2) CA2881096C (https=)
WO (1) WO2014026117A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110464709A (zh) 2012-08-10 2019-11-19 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
JP6625966B2 (ja) 2013-03-15 2019-12-25 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 希ガスが豊富な液体ならびにその調製及び使用の方法
US10456483B2 (en) 2014-12-03 2019-10-29 University Of Cincinnati Gas-encapsulated acoustically responsive stabilized microbubbles and methods for treating cardiovascular disease
US10500227B2 (en) * 2014-12-03 2019-12-10 University Of Cincinnati Bioactive gas-encapsulated echogenic liposomes and methods for treating cardiovascular disease
AU2016281656B2 (en) * 2015-06-23 2019-05-30 Nobilis Therapeutics, Inc. Therapeutic immune modulation using noble gas compositions
EP3158992A1 (en) * 2015-10-21 2017-04-26 Universität Heidelberg Liposomes containing cell penetrating peptides and tetraetherlipids for the oral delivery of macromolecules
CZ307851B6 (cs) 2017-02-14 2019-06-26 Ústav experimentální medicíny AV ČR, v. v. i. Léčebný přípravek k prevenci a léčení zánětlivých a degenerativních onemocnění
JP2020033304A (ja) * 2018-08-30 2020-03-05 医療法人ふじいやさか 薬剤又はサプリメント、組成物、及び水素供給器の使用
EP3628309A1 (en) 2018-09-28 2020-04-01 Universität Heidelberg Method of making oral dosage forms
JP7716076B2 (ja) * 2021-02-04 2025-07-31 学校法人産業医科大学 血管内穿孔によるくも膜下出血モデルの血腫を可視化する方法
JP2022144013A (ja) * 2021-03-18 2022-10-03 橋本電子工業株式会社 抗血栓リポソーム

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4162282A (en) 1976-04-22 1979-07-24 Coulter Electronics, Inc. Method for producing uniform particles
US4310505A (en) 1979-11-08 1982-01-12 California Institute Of Technology Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
US4533254A (en) 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
US5030453A (en) 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US4728575A (en) 1984-04-27 1988-03-01 Vestar, Inc. Contrast agents for NMR imaging
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
IL79559A0 (en) 1986-07-29 1986-10-31 Univ Ramot Contrast agents for nmr medical imaging
US4728578A (en) 1986-08-13 1988-03-01 The Lubrizol Corporation Compositions containing basic metal salts and/or non-Newtonian colloidal disperse systems and vinyl aromatic containing polymers
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5228446A (en) 1989-12-22 1993-07-20 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5305757A (en) 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5639441A (en) 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
US5858399A (en) 1992-04-09 1999-01-12 Northwestern University Acoustically reflective liposomes and methods to make and use the same
WO1993020802A1 (en) 1992-04-09 1993-10-28 Northwestern University Acoustically reflective liposomes and methods to make and use the same
NZ262679A (en) 1993-02-22 1997-08-22 Vivorx Pharmaceuticals Inc Compositions for in vivo delivery of pharmaceutical agents where the agents are contained in a polymeric shell
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US5545396A (en) 1994-04-08 1996-08-13 The Research Foundation Of State University Of New York Magnetic resonance imaging using hyperpolarized noble gases
US6123919A (en) 1994-04-08 2000-09-26 The Trustees Of Princeton University Magnetic resonance imaging using hyperpolarized noble gases
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
WO1997015311A1 (fr) 1995-10-20 1997-05-01 L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Composition a base de monoxyde d'azote en tant que medicament
US6770291B2 (en) 1996-08-30 2004-08-03 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
US6413544B1 (en) 1996-08-19 2002-07-02 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
US5891467A (en) 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US6548047B1 (en) * 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6050444A (en) 1998-07-22 2000-04-18 Sugg; James Wesley Consumable beverage dispenser with one-way valve
DE19910986C2 (de) 1999-03-11 2001-06-07 Aga Ab Verwendung von Xenon bei der Behandlung von Neurointoxikationen
GB9913677D0 (en) 1999-06-11 1999-08-11 Imperial College Formulation
DE19933704A1 (de) 1999-07-19 2001-01-25 Michael Georgieff Verwendung einer lipophile Gase enthaltenden Präparation zur Neuroprotektion und Neuroregeneration
US6653354B2 (en) 1999-07-29 2003-11-25 Protexeon Limited NMDA antagonist comprising xenon
GB9917822D0 (en) 1999-07-29 1999-09-29 Imperial College Nmda antagonist
US6680068B2 (en) 2000-07-06 2004-01-20 The General Hospital Corporation Drug delivery formulations and targeting
DE10054563A1 (de) 2000-11-03 2002-05-16 Messer Griesheim Gmbh Verfahren und Vorrichtung zur Betonherstellung
AU2002220881A1 (en) 2000-12-04 2002-06-18 Uws Ventures Limited Noble gas complexes
ES2243350T3 (es) 2001-01-31 2005-12-01 Bracco International B.V. Agente de contraste liofizable que comprende microburbujas de gas.
EP1399189A1 (en) 2001-06-11 2004-03-24 Universite De Montreal Compositions and methods for enhancing nucleic acid transfer into cells
JP5170934B2 (ja) 2001-08-16 2013-03-27 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 改良ｄｎａリポフェクションならびに／または徐放性プロドラッグおよび薬物療法のための試薬の合成と使用
US7202089B2 (en) 2001-09-14 2007-04-10 Alan Kleinfeld Early diagnosis of stroke
GB0209998D0 (en) 2002-05-01 2002-06-12 Protexeon Ltd Use
CN1668315A (zh) * 2002-06-12 2005-09-14 梅瑟·格里斯海姆有限公司 使用含氙气体进行脑保护
DE10328272A1 (de) 2002-06-22 2004-01-15 Messer Griesheim Gmbh Medikament mit Xenon und NO
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
JP2006508040A (ja) 2002-07-05 2006-03-09 メツサー グリースハイム ゲゼルシヤフト ミツト ベシユレンクテル ハフツング キセノンを含有するアジュバント
GB0218153D0 (en) 2002-08-05 2002-09-11 Ic Innovations Ltd An analgesic agent for newborn or retal subjects
DE10336778B4 (de) 2002-08-10 2010-09-16 Air Liquide Deutschland Gmbh Stabilisierung eines Patienten mit einem xenonhaltigen Gas
DE10336768B4 (de) 2002-08-10 2010-09-09 Air Liquide Deutschland Gmbh Medikament zur Verbesserung der Sauerstoffutilation
US20050008617A1 (en) 2002-09-28 2005-01-13 Massachusetts Institute Of Technology Compositions and methods for delivery of short interfering RNA and short hairpin RNA
EP1575562B1 (en) 2002-11-26 2016-10-05 Seacoast Neurosciene, Inc. Buoyant polymer particles delivering therapeutic agents
US20040208921A1 (en) 2003-01-14 2004-10-21 Ho Rodney J. Y. Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
FR2849779B1 (fr) 2003-01-15 2006-07-14 Air Liquide Sante Sa Utilisation de xenon ou de n2o dans le traitement des deteriorations cellulaires cerebrales post-ischemiques
US7198179B2 (en) 2003-02-25 2007-04-03 Therox, Inc. System for storing and dispensing a gas-solubilized product
US20060019868A1 (en) 2004-01-30 2006-01-26 Pendharkar Sanyog M Hemostatic compositions and devices
WO2005034966A1 (en) 2003-10-10 2005-04-21 Protexeon Limited Use of xenon with hypothermia for treating neonatal asphyxia
EP1552840A1 (en) 2004-01-07 2005-07-13 Aga Ab Use of a xenon/carbon monoxide mixture for the protection of cells
GB0418540D0 (en) 2004-08-19 2004-09-22 Protexeon Ltd Use
EP1714642A1 (en) * 2005-04-18 2006-10-25 Bracco Research S.A. Pharmaceutical composition comprising gas-filled microcapsules for ultrasound mediated delivery
CA2609373A1 (en) 2005-05-23 2006-11-30 Mebiopharm Co., Ltd. Method of producing liposomes containing gas enclosed therein
CN101437485A (zh) 2006-05-09 2009-05-20 高露洁-棕榄公司 口腔护理方案
US7976743B2 (en) * 2006-10-16 2011-07-12 Northwestern University Gas-containing liposomes
US20080187605A1 (en) 2007-02-02 2008-08-07 Olney John W Preventing pathological nerve cell suicide (neuroapoptosis) in immature nervous systems
US9814672B2 (en) 2007-03-09 2017-11-14 Susan T. Laing Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi
EP1980260A1 (en) 2007-04-10 2008-10-15 Nicholas Peter Franks Use of hyperbaric conditions to provide neuroprotection
WO2008132239A1 (en) 2007-04-30 2008-11-06 Nnoxe Pharmaceutiques Inc Pharmaceutical composition comprising at least one thrombolytic agent (a) and at least one gas (b) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon
ITMI20071031A1 (it) 2007-05-22 2008-11-23 Acetilene & Deriv Ati Siad Spa Uso di xenon per la protezione di organi da danno ischemico
US20110104052A1 (en) * 2007-12-03 2011-05-05 The Johns Hopkins University Methods of synthesis and use of chemospheres
EP2222279A2 (en) 2007-12-10 2010-09-01 Epitarget AS Acoustically sensitive drug delivery particles comprising non-lamellar forming lipids
CL2007003772A1 (es) 2007-12-21 2008-04-25 Vulco Sa Procedimiento para la fabricacion de un mandril flexible de poliuretano, que contiene un alma metalica que comprende recubrir con goma un alma metalica, aplicar desmoldante, precalentar el conjunto, curar el poliuretano y enfriar el codo.
US8618056B2 (en) * 2007-12-22 2013-12-31 Cuthbert O. Simpkins Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
LT2349300T (lt) 2008-11-10 2019-10-25 Moleac Pte Ltd Kombinuota terapija pacientų su neurologiniais sutrikimais ir smegenų infarktu gydymui
CN102300555B (zh) 2009-01-30 2015-06-17 卡斯伯特·O·辛普金斯 复苏液
FR2944969B1 (fr) 2009-04-29 2011-08-26 Air Liquide Utilisation de n2o gazeux dans le traitement des douleurs chroniques
CA2761455C (en) * 2009-05-13 2018-06-12 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
EP2445339B1 (en) * 2009-06-22 2019-08-07 Diffusion Pharmaceuticals LLC Diffusion enhancing compound and its use with a thrombolytic
WO2011091160A1 (en) 2010-01-20 2011-07-28 Henry Wu Custom-formulated phospholipid microbubbles and methods and uses thereof
FR2956323B1 (fr) 2010-02-15 2013-12-20 Air Liquide Medicament gazeux inhalable a base d'argon contre les deficiences ou defaillances d'organes peripheriques
WO2012020030A1 (en) 2010-08-09 2012-02-16 Bracco Suisse Sa Targeted gas-filled microvesicles
CN103491976B (zh) 2011-01-14 2015-04-01 卡思伯特·O·辛普金斯 用于处理与缺乏血液供给、休克和神经损伤相关的疾病的方法和组合物
US20130247924A1 (en) 2012-03-23 2013-09-26 Mark Scatterday Electronic cigarette having a flexible and soft configuration
CN110464709A (zh) 2012-08-10 2019-11-19 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法

Also Published As

Publication number Publication date
EP2882422A4 (en) 2016-03-16
US10973764B2 (en) 2021-04-13
US20200101015A1 (en) 2020-04-02
CA3132444A1 (en) 2014-02-13
US20210378959A1 (en) 2021-12-09
EP2882422A2 (en) 2015-06-17
CA2881096A1 (en) 2014-02-13
US10369103B2 (en) 2019-08-06
AU2013299453B2 (en) 2017-12-14
AU2013299453A1 (en) 2015-02-26
JP6297040B2 (ja) 2018-03-20
CN103565745A (zh) 2014-02-12
CA3132444C (en) 2023-11-07
EP3932394B1 (en) 2024-08-07
JP2015528441A (ja) 2015-09-28
EP3932394A1 (en) 2022-01-05
CN110464709A (zh) 2019-11-19
US20240398708A1 (en) 2024-12-05
EP2882422B1 (en) 2021-04-28
US20150216800A1 (en) 2015-08-06
WO2014026117A3 (en) 2014-10-23
US11872312B2 (en) 2024-01-16
WO2014026117A2 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
US11872312B2 (en) Neuroprotective liposome compositions and methods for treatment of stroke
JP4555569B2 (ja) 増強された血中安定性を有する脂質キャリア組成物
US7976743B2 (en) Gas-containing liposomes
KR101076053B1 (ko) 초음파 조영제 및 그것의 제조방법
US12070512B2 (en) Targeted gas-filled microvesicles formulation
JP2018502870A (ja) トラネキサム酸の多小胞リポソーム処方物
US20080008658A1 (en) Contrast Agent Formulations for the Visualization of the Lymphatic System
JP6903318B2 (ja) 一酸化窒素内包バブルリポソーム及びその利用
Uhl et al. Reduction of skin flap necrosis by transdermal application of buflomedil bound to liposomes
HK40017554A (en) Neuroprotective liposome compositions and methods for treatment of stroke
HK1193995A (en) Neuroprotective liposome compositions and methods for treatment of stroke
HK1240506B (zh) 靶向的充气微囊制剂
Wang Studies on temperature-sensitive liposomes for targeted delivery to the eye
HK1240506A1 (en) Targeted gas-filled microvesicles formulation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180725

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240726